Almirall Aims To Disrupt Actinic Keratosis Space With Klisyri
Gel Gets Backing Of The EMA
Helped by its convenient five-day dosing, the shortest of any topical treatment for the precancerous skin disease, the Spanish company believes Klisyri, already launched in the US, will become a popular alternative to current options for actinic keratosis.
You may also be interested in...
The latest drug safety actions by the European Medicines Agency affect products for dermatological use and vaginal atrophy.
Dermira hopes to move into Phase III quickly with IL-13 inhibitor lebrikizumab, looking at monthly dosing in the maintenance setting. Efficacy in Phase IIb appears similar to Sanofi/Regeneron’s Dupixent.
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440, its TRPV1 antagonist for neuropathic pain.